106 related articles for article (PubMed ID: 18980547)
1. The changing paradigm of colorectal cancer therapy: the impact of vascular endothelial growth factor and epidermal growth factor and epidermal growth factor receptor inhibition. Introduction.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):17S. PubMed ID: 18980547
[No Abstract] [Full Text] [Related]
2. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
Engstrom PF;
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
[TBL] [Abstract][Full Text] [Related]
3. Metastatic colorectal cancer.
Saletti P; Cavalli F
Cancer Treat Rev; 2006 Nov; 32(7):557-71. PubMed ID: 16935430
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for colorectal cancer.
Hwang J; Marshall JL
Curr Opin Investig Drugs; 2006 Dec; 7(12):1062-6. PubMed ID: 17209523
[TBL] [Abstract][Full Text] [Related]
5. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
6. Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma.
Venook AP
Cancer; 2005 Jun; 103(12):2435-46. PubMed ID: 15880563
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer.
Wilson RH
Oncologist; 2006 Oct; 11(9):1018-24. PubMed ID: 17030644
[TBL] [Abstract][Full Text] [Related]
8. Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
Marshall JL
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S63-6. PubMed ID: 19064409
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the management of metastatic colorectal cancer.
Comella P; Casaretti R; Avallone A; Franco L
Crit Rev Oncol Hematol; 2010 Jul; 75(1):15-26. PubMed ID: 19837601
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Morse MA
IDrugs; 2005 Dec; 8(12):974-7. PubMed ID: 16320126
[No Abstract] [Full Text] [Related]
11. Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.
Adams R; Maughan T
Expert Rev Anticancer Ther; 2007 Apr; 7(4):503-18. PubMed ID: 17428171
[TBL] [Abstract][Full Text] [Related]
12. Commentary: targeting colorectal cancer through molecular biology.
Kumar R
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S37-9. PubMed ID: 16399429
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy in colorectal cancer: do we know enough?
Pantaleo MA; Palassini E; Labianca R; Biasco G
Dig Liver Dis; 2006 Feb; 38(2):71-7. PubMed ID: 16289975
[TBL] [Abstract][Full Text] [Related]
14. Clinical predictive factors.
Köhne CH; Vanhoefer U; Hartung G
Eur J Cancer; 2009 Sep; 45 Suppl 1():43-9. PubMed ID: 19775603
[No Abstract] [Full Text] [Related]
15. Dual VEGF/EGFR inhibition versus single targeted agent treatment in patients with metastatic colorectal cancer: a meta-analysis of randomized trials.
Li X; Wang M; Liu GY; Ma JL
Int J Colorectal Dis; 2016 Sep; 31(9):1655-6. PubMed ID: 27129852
[No Abstract] [Full Text] [Related]
16. Esophageal cancer: current and emerging therapy modalities.
Ekman S; Dreilich M; Lennartsson J; Wallner B; Brattström D; Sundbom M; Bergqvist M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1433-48. PubMed ID: 18759695
[TBL] [Abstract][Full Text] [Related]
17. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer.
Lacouture ME
Cancer Nurs; 2007; 30(4 Suppl 1):S17-26. PubMed ID: 17666987
[TBL] [Abstract][Full Text] [Related]
18. [An new generation of antineoplastic agents--targeted therapy in gastrointestinal tumors].
Lang A; Graeven U
Zentralbl Chir; 2009 Jun; 134(3):189-92. PubMed ID: 19544236
[No Abstract] [Full Text] [Related]
19. Cardiovascular toxicity of molecularly targeted agents.
Strevel EL; Siu LL
Eur J Cancer; 2009 Sep; 45 Suppl 1():318-31. PubMed ID: 19775628
[No Abstract] [Full Text] [Related]
20. Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
Carles J; Morales R; Perez JM; Suárez C; Rodón J; Valverde C
Eur J Cancer; 2009 Sep; 45 Suppl 1():309-17. PubMed ID: 19775627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
